Evidence map›Paper›PMID 40664938›Full record

ArticleCommunications biology2025

Deciphering cancer therapy resistance via patient-level single-cell transcriptomics with CellResDB.

Tianyuan Liu, Huiyuan Qiao, Liping Ren, Xiucai Ye, Quan Zou, Yang Zhang

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tianyuan Liu *Innovative Institute of Chinese Medicine and Pharmacy, Academy for Interdiscipline, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.ORCID http://orcid.org/0000-0001-7367-8128
Huiyuan Qiao *School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Liping RenSchool of Healthcare Technology, Chengdu Neusoft University, Chengdu, 611844, China.
Xiucai YeTsukuba Life Science Innovation Program, University of Tsukuba, Tsukuba, 3058577, Japan. yexiucai@cs.tsukuba.ac.jp.ORCID http://orcid.org/0000-0002-5547-3919
Quan ZouInstitute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu, 611731, China. zouquan@nclab.net.ORCID http://orcid.org/0000-0001-6406-1142
Yang ZhangInnovative Institute of Chinese Medicine and Pharmacy, Academy for Interdiscipline, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. zhy1001@alu.uestc.edu.cn.ORCID http://orcid.org/0000-0002-1317-120X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 62131004
6 · The paper itself

Abstract

Cancer therapy resistance remains a major challenge, with limited resources available for systematically studying its underlying mechanisms at the patient level. The existing databases are either restricted to bulk RNA-seq data, lack single-cell resolution, or provide limited clinical annotations, making them insufficient for in-depth exploration of the tumor microenvironment (TME) dynamics in therapy resistance. To bridge this gap, we present CellResDB, a patient-derived platform comprising nearly 4.7 million cells from 1391 patient samples across 24 cancer types. CellResDB provides comprehensive annotations of TME features linked to therapy resistance. To enhance accessibility, we include an intelligent robot, CellResDB-Robot, which facilitates intuitive data retrieval and analysis. In summary, CellResDB represents a valuable resource for cancer therapy and provides an experimental protocol for applying large language models (LLMs) within the biomedical database. CellResDB is freely available at https://cellknowledge.com.cn/cellresponse .

Indexed as

Databases, GeneticDrug Resistance, NeoplasmNeoplasmsSingle-Cell AnalysisTranscriptomeGene Expression ProfilingHumansTumor Microenvironment

Identifiers

PMID40664938
PMCPMC12264041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.